The first report of the Italian Migraine Registry (I-GRAINE)

• DOI: 10.1007/s10072-022-06214-5
• Publication Date: 2022-07-08T11:02:54Z
• Authors: Piero Barbanti; Gabriella Egeo; Cinzia Aurilia; Giulia Fiorentini; Stefania Proietti; Carlo Tomino; Stefano Bonassi; ; Maria Albanese; Giovanni Allais; Claudia Altamura; Marco Aguggia; Massimo Autunno; Patrizia Balsamo; Marco Bartoli; Maria Bloise; Chiara Benedetto; Francesco Bono; Giovanni Caggia; Cecilia Camarda; Antonio Carnevale; Alessandra Cerchi; Sabina Cevoli; Bruno Colombo; Alfonso Coppola; Roberto De Simone; Laura Di Clemente; Paola Di Fiore; Alfonsina Di Summa; Florindo d’Onofrio; Valentina Favoni; Massimo Filippi; Cinzia Finocchi; Fabio Frediani; Licia Grazzi; Rosario Grugno; Andrea Mancioli; Roberta Messina; Stefano Messina; Franca Moschiano; Claudio Mostardini; Matteo Paolucci; Francesco Perini; Giulia Pierangeli; Pietro Querzani; Renata Rao; Steno Rinalduzzi; Marco Russo; Erminia Stochino; Silvia Strumia; Paola Torelli; Fabio Valguerra; Fabrizio Vernieri; Giovanna Viticchi; Maurizio Zucco
• Keywords: Registrie; Male; Registry; Healthcare resource use; Migraine Disorders; Headache; 610; Healthcare resource use; Migraine; Patient’s journey; Registry; Treatment; Tryptamine; Tryptamines; Treatment; Prospective Studie; 03 medical and health sciences; 0302 clinical medicine; Humans; Female; Prospective Studies; Registries; Healthcare resource use; Migraine; Patient’s journey; Registry; Treatment; Female; Headache; Humans; Male; Prospective Studies; Registries; Tryptamines; Migraine Disorders; Patient’s journey; Migraine; Human

Italian Migraine Registry (I-GRAINE) is a multicenter (n = 38), prospective, observational, non-interventional study aimed at providing big data on migraine to ensure proper clinical disease management, according to scientific, and sustainability criteria. We enrolled consecutive patients affected by episodic or chronic migraine according to the systematic random method. Information on sociodemographic characteristics, lifestyle, migraine features, patient's journey, and healthcare resource use were gathered using face-to-face interviews.On the date of 31 December 2021, we enrolled 231 patients at 12 headache centers. Most of them were women (84.4%), with high migraine frequency (9.6 ± 6.9 days/month) and severe disability (MIDAS score: 43.0 ± 40.8; HIT-6 score: 60.4 ± 10.6). Only a minority of patients (38.1%) had previously visited a headache center.A clear-cut difference emerged in the proportion of responders to nonspecific acute treatments (43.5-66.7%) compared to triptans (76.3%) and in responders to unspecific prophylaxis (5.4-35%) compared to anti-CGRP monoclonal antibodies (69.2-78.6%). Most patients underwent ≥ 1 specialist visit (66.9%) or diagnostic investigation (77.4%) over the last 3 years-mostly subsidized by our national health system-inappropriate in 64.9% and 25% of the cases, respectively.The I-GRAINE registry is expected to provide a large and exponentially increasing collection of clinical, biological, and epidemiologic information and will contribute to moving migraine out of the shadow cone of marginalization, which has been often relegated up to now.